Halia Therapeutics, Inc.

ACTIVE

3900 N Traverse Mountain Blvd Ste 100, 犹他州犹他县, 犹他州, United Stateswww.haliatherapeutics.comHolding11–50 employeesEstablished: 2017-01-01

Clinical Trials

2 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2017

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

71.4%

Phase 1

28.6%

Trial Status Distribution

Active, not recruiting

14.3%

Completed

42.9%

Not yet recruiting

14.3%

Recruiting

14.3%

Withdrawn

14.3%

Clinical Trials

Trials sponsored by this organization (7)

Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Transfusions

Phase 2

Not yet recruiting

interventional

Oct 202650 participants

Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers

Phase 2

Recruiting

interventional

May 2026112 participants

A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

Phase 2

Withdrawn

interventional

Jan 202650 participants

Study to Evaluate HT-4253 in Healthy Subjects

Phase 1

Completed

interventional

Sep 202480 participants

Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction

Phase 2

Completed

interventional

Feb 202481 participants

A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia

Phase 2

Active, not recruiting

interventional

Dec 202337 participants

Study to Evaluate HT-6184 in Healthy Subjects

Phase 1

Completed

interventional

Jun 202264 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations